Advances in prostate cancer surgery in New Zealand
New Zealand's Kasseln Kilgure Center (KKC) has treated the first patient of Augmenix's SpaceOAR system. This is a medical device that protects men from rectal complications after radiation therapy of prostate cancer.
As the prostate and rectum are anatomically adjacent, radiotherapy targeting the prostate may damage the rectum and cause pain, discomfort or diarrhea.
The SpaceOAR system works by injecting the hydrogel into the space between the prostate and the rectum and produces a force to push the organs away from one another. As a result, during prostate radiation therapy, the rectum is out of the area affected by radiation and is less damaged.
Dr. Leanne Tyrie, clinical director of KKC, said, "KKC is dedicated to providing the best care for patients, and the introduction of SpaceOAR hydrogels for prostate cancer males is no longer necessary to achieve this It is one step. " "Significant reductions in intestinal, urinary and sexual side effects after radiation therapy using SpaceOAR hydrogel have decided to incorporate it as part of the criteria for caring for prostate cancer patients."
In addition to increasing rectal protection, hydrogels can also reduce radiation and harmful side effects to urine and genitals.
The hydrogel keeps the interval for 3 months, gradually becomes liquid and is excreted in urine by kidney filtration for about 6 months after injection.
"According to recent clinical data, SpaceOAR hydrogels have been shown to be helpful in significantly reducing the risk of side effects of rectal and side effects and loss of sexual function associated with radiation therapy in the treatment of prostate cancer," Augmenix CEO John Pedersen said. "The first patient treated with New Zealand's SpaceOAR hydrogel is proud to offer treatment for high quality, multi-modality radiation therapy for men who have been diagnosed with prostate cancer. At the Kathleen Kilgour Center I am glad that I was.
Augemix, based in Bedford, Massachusetts, evaluates the safety of male systems undergoing image induced intensity modulated radiation therapy (IG-IMRT) and evaluates whether it is using SpaceOAR hydrogel weight loss exposure For phase III clinical trials in the US (NCT 0 055 6, 628) exposure to the rectum.
The results showed that the hydrogel spacer is safe and tolerable. It decreased the report of pain during treatment and significantly reduced rectal radiation injury. One year after radiotherapy, the rectal complications decreased by 71%, and those who did not inject hydrogel had 3.5 times the incidence of rectal complications.
Three years after treatment, patients treated with SpaceOAR had reduced rectal radiation dose by 73.5% and improved urinary function and sexual function.
Men who received SpaceOAR are eight times less likely to experience a marked decline in quality of life, 78% of men who were sexually active before receiving SpaceOAR treatment may retain sexual function in 3 years Was high.
EmoticonEmoticon